Transcriptional activity of TAp63 promoter is regulated by c-jun

Journal of Cellular Physiology

Volumn 225, Issue 3, 2010, Pages 898-904

  Yao, Jeng Yuan ^a   Pao, Chia Chu ^a   Chen, Jan Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PROTEIN C JUN; PROTEIN P53; PROTEIN P63; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BINDING SITE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; UPREGULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; REPORTER GENE; RNA INTERFERENCE; TIME; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN; RNA INTERFERENCE; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 77957745623     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22300     Document Type: Article

References (48)

1. Akatsu Y, Saikawa Y, Kubota T, Akatsu T, Yoshida M, Kitagawa Y, Otani Y, Kumai K, Kitajima M. 2007. Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. Cancer Sci 98: 707-715.
2. Angel P, Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157.
3. Bakkers J, Camacho-Carvajal M, Nowak M, Kramer C, Danger B, Hammerschmidt M. 2005. Destabilization of DeltaNp63alpha by Nedd4-mediated ubiquitination and Ubc9-mediated sumoylation, and its implications on dorsoventral patterning of the zebrafish embryo. Cell Cycle 4: 790-800.
4. Barbieri CE, Pietenpol JA. 2006. p63 and epithelial biology. Exp Cell Res 312: 695-706.
5. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. 2006. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66: 7589-7597.
6. Biggs TE, Cooke SJ, Barton CH, Harris MP, Saksela K, Mann DA. 1999. Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 NEF is a cell-type-specific response that requires both hck and MAPK signaling events. J Mol Biol 290: 21-35.
7. Chen X. 1999. The p53 family: Same response, different signals? Mol Med Today 5: 387-392.
8. Chen BK, Chang WC. 2000. Functional interaction between c-Jun and promoter factor Sp1 in epidermal growth factor-induced gene expression of human 12(S)-lipoxygenase. Proc Natl Acad Sci USA 97: 10406-10411.
9. Chen BK, Huang CC, Chang WC, Chen YJ, Kikkawa U, Nakahama K, Morita I, Chang WC. 2007. PP2B-mediated dephosphorylation of c-Jun C terminus regulates phorbol ester-induced c-Jun/Sp1 interaction in A431 cells. Mol Biol Cell 18: 1118-1127.
10. Chu WK, Dai PM, Li HL, Chen JK. 2008. Transcriptional activity of the DeltaNp63 promoter is regulated by STAT3. J Biol Chem 283: 7328-7337.
11. Domann FE, Levy JP, Birrer MJ, Bowden GT. 1994. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ 5: 9-16.
12. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564.
13. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, Vogel H, Mills AA. 2009. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 11: 1451-1457.
14. Hess J, Angel P, Schorpp-Kistner M. 2004. AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
15. Hickman ES, Helin K. 2000. The p53 tumour suppressor protein. Biotechnol Genet Eng Rev 17: 179-211.
16. Huang CC, Wang JM, Kikkawa U, Mukai H, Shen MR, Morita I, Chen BK, Chang WC. 2008. Calcineurin-mediated dephosphorylation of c-Jun Ser-243 is required for c-Jun protein stability and cell transformation. Oncogene 27: 2422-2429.
17. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819.
18. Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, Ando N, Takizawa T, Kageyama Y, Kihara K. 2003. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9: 5501-5507.
19. Komatsu S, Takenobu H, Ozaki T, Ando K, Koida N, Suenaga Y, Ichikawa T, Hishiki T, Chiba T, Iwama A, Yoshida H, Ohnuma N, Nakagawara A, Kamijo T. 2009. Plk1 regulates liver tumor cell death by phosphorylation of TAp63. Oncogene 28: 3631-3641.
20. Koster MI, Roop DR. 2004. Transgenic mouse models provide new insights into the role of p63 in epidermal development. Cell Cycle 3: 411-413.
21. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. 2004. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 18: 126-131.
22. Koster MI, Lu SL, White LD, Wang XJ, Roop DR. 2006. Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res 66: 3981-3986.
23. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. 2008. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 27: 741-754.
24. Levrero M, De L V, Costanzo A, Gong J, Wang JY, Melino G. 2000. The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 113: 1661-1670.
25. Li Y, Zhou Z, Chen C. 2008. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15: 1941-1951.
26. Liu DS, Krebs CE, Liu SJ. 2007a. Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-alpha. J Cell Biochem 101: 517-528.
27. Liu YW, Chen CC, Wang JM, Chang WC, Huang YC, Chung SY, Chen BK, Hung JJ. 2007b. Role of transcriptional factors Sp1, c-Rel, and c-Jun in LPS-induced C/EBPdelta gene expression of mouse macrophages. Cell Mol Life Sci 64: 3282-3294.
28. Lu C, Li Y, Zhao Y, Xing G, Tang F, Wang Q, Sun Y, Wei H, Yang X, Wu C, Chen J, Guan KL, Zhang C, Chen H, He F. 2002. Intracrine hepatopoietin potentiates AP-1 activity through JAB1 independent of MAPK pathway. FASEB J 16: 90-92.
29. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. 1999. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
30. Milstein D, Robinson E. 1981. Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide and CCNU. Cancer 48: 2358-2363.
31. Osada M, Inaba R, Shinohara H, Hagiwara M, Nakamura M, Ikawa Y. 2001. Regulatory domain of protein stability of human P51/TAP63, a P53 homologue. Biochem Biophys Res Commun 283: 1135-1141.
32. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, de Caron FC. 2005. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene 24: 512-519.
33. Piazza E, Donelli MG, Broggini M, Sessa C, Natale N, Ottolenghi L, Marsoni S, Libretti A, Mangioni C, Morasca L. 1980. Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy. Cancer Treat Rep 64: 845-854.
34. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. 2003. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443: 122-132.
35. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, Croce CM, Melino G. 2006. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 103: 12753-12758.
36. Schultz J, Ponting CP, Hofmann K, Bork P. 1997. SAM as a protein interaction domain involved in developmental regulation. Protein Sci 6: 249-253.
37. Shaulian E, Karin M. 2001. AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400.
38. Shaulian E, Karin M. 2002. AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136.
39. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. 1999. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070.
40. Suenaga Y, Ozaki T, Tanaka Y, Bu Y, Kamijo T, Tokuhisa T, Nakagawara A, Tamura TA. 2009. TBP (TATA-binding protein)-like protein (TLP) is engaged in etoposide-induced apoptosis through transcriptional activation of humanTAp63 gene. J Biol Chem 284: 35433-35440.
41. Thanos CD, Bowie JU. 1999. p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci 8: 1708-1710.
42. Tsou JH, Chang KY, Wang WC, Tseng JT, Su WC, Hung LY, Chang WC, Chen BK. 2008. Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells. Nucleic Acids Res 36: 217-227.
43. Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW, Chen SL. 2000. Transcriptional repression of p21((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site. Biochem Biophys Res Commun 270: 303-310.
44. Watson IR, Irwin MS. 2006. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8: 655-666.
45. Wu Y, Zhang X, Zehner ZE. 2003. c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1. Oncogene 22: 8891-8901.
46. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
47. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F. 1999. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
48. Yen CC, Chen YJ, Pan CC, Lu KH, Chen PC, Hsia JY, Chen JT, Wu YC, Hsu WH, Wang LS, Huang MH, Huang BS, Hu CP, Chen PM, Lin CH. 2005. Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed. World J Gastroenterol 11: 1267-1272.